Laboratory Medicine ›› 2020, Vol. 35 ›› Issue (5): 476-480.DOI: 10.3969/j.issn.1673-8640.2020.05.018
Previous Articles Next Articles
Received:
2019-10-26
Online:
2020-05-30
Published:
2020-06-17
CLC Number:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2020.05.018
项目 | 总x | 批内s | 批间s | 批间方差 | 总方差 | 实验室内s | 实验室内CV/% |
---|---|---|---|---|---|---|---|
HbsAg/(IU/mL) | |||||||
低值 | 1.62 | 0.05 | 0.03 | 0.00 | 0.00 | 0.05 | 2.88 |
高值 | 2.55 | 0.04 | 0.03 | 0.00 | 0.00 | 0.05 | 1.83 |
HbsAb/(mIU/m) | |||||||
低值 | 22.33 | 0.66 | 0.26 | 0.07 | 0.36 | 0.60 | 2.67 |
高值 | 174.27 | 5.55 | 1.08 | 1.18 | 21.69 | 4.66 | 2.67 |
HbeAg/(PEIU/mL) | |||||||
低值 | 7.16 | 0.40 | 0.05 | 0.00 | 0.11 | 0.33 | 4.60 |
高值 | 15.53 | 0.58 | 0.09 | 0.01 | 0.23 | 0.48 | 3.09 |
HBeAb/(PEIU/mL) | |||||||
低值 | 3.59 | 0.23 | 0.13 | 0.02 | 0.05 | 0.23 | 6.31 |
高值 | 5.27 | 0.26 | 0.15 | 0.02 | 0.07 | 0.26 | 4.94 |
HBcAb/(PEIU/mL) | |||||||
低值 | 2.12 | 0.11 | 0.04 | 0.00 | 0.01 | 0.10 | 4.57 |
高值 | 4.22 | 0.18 | 0.06 | 0.00 | 0.03 | 0.18 | 3.73 |
PreS1Ag/(AU/mL) | |||||||
低值 | 73.68 | 2.31 | 0.99 | 0.97 | 4.53 | 2.13 | 2.89 |
高值 | 149.05 | 6.44 | 1.80 | 3.23 | 30.86 | 5.56 | 3.73 |
项目 | 总x | 批内s | 批间s | 批间方差 | 总方差 | 实验室内s | 实验室内CV/% |
---|---|---|---|---|---|---|---|
HbsAg/(IU/mL) | |||||||
低值 | 1.62 | 0.05 | 0.03 | 0.00 | 0.00 | 0.05 | 2.88 |
高值 | 2.55 | 0.04 | 0.03 | 0.00 | 0.00 | 0.05 | 1.83 |
HbsAb/(mIU/m) | |||||||
低值 | 22.33 | 0.66 | 0.26 | 0.07 | 0.36 | 0.60 | 2.67 |
高值 | 174.27 | 5.55 | 1.08 | 1.18 | 21.69 | 4.66 | 2.67 |
HbeAg/(PEIU/mL) | |||||||
低值 | 7.16 | 0.40 | 0.05 | 0.00 | 0.11 | 0.33 | 4.60 |
高值 | 15.53 | 0.58 | 0.09 | 0.01 | 0.23 | 0.48 | 3.09 |
HBeAb/(PEIU/mL) | |||||||
低值 | 3.59 | 0.23 | 0.13 | 0.02 | 0.05 | 0.23 | 6.31 |
高值 | 5.27 | 0.26 | 0.15 | 0.02 | 0.07 | 0.26 | 4.94 |
HBcAb/(PEIU/mL) | |||||||
低值 | 2.12 | 0.11 | 0.04 | 0.00 | 0.01 | 0.10 | 4.57 |
高值 | 4.22 | 0.18 | 0.06 | 0.00 | 0.03 | 0.18 | 3.73 |
PreS1Ag/(AU/mL) | |||||||
低值 | 73.68 | 2.31 | 0.99 | 0.97 | 4.53 | 2.13 | 2.89 |
高值 | 149.05 | 6.44 | 1.80 | 3.23 | 30.86 | 5.56 | 3.73 |
项目 | 使用前(2019年3月) | 使用后(2019年8月) | ||||
---|---|---|---|---|---|---|
样本数 | TAT/min | 90%样本完成 时间/min | 样本数 | TAT/min | 90%样本完成 时间/min | |
8:00—10:30接收 | 2 154 | 2 700 | ||||
接收到审核 | 353(325~384) | 421 | 231(158~280) | 360* | ||
录入到审核 | 308(258~349) | 377 | 143(103~202) | 247* | ||
8:00—15:00接收 | 3 113 | 3 742 | ||||
接收到审核 | 366(322~1 569) | 1 698 | 214(147~279) | 359* | ||
录入到审核 | 308(249~352) | 385 | 128(90~191) | 241* | ||
8:00—15:00接收 | 866 | 121 | ||||
但未出报告 | ||||||
接收到审核 | 1 661(1 610~1 780) | 3 186 | 1 530(1 404~1 606) | 1 775* | ||
录入到审核 | 350(257~396) | 413 | 163(95~299) | 354* |
项目 | 使用前(2019年3月) | 使用后(2019年8月) | ||||
---|---|---|---|---|---|---|
样本数 | TAT/min | 90%样本完成 时间/min | 样本数 | TAT/min | 90%样本完成 时间/min | |
8:00—10:30接收 | 2 154 | 2 700 | ||||
接收到审核 | 353(325~384) | 421 | 231(158~280) | 360* | ||
录入到审核 | 308(258~349) | 377 | 143(103~202) | 247* | ||
8:00—15:00接收 | 3 113 | 3 742 | ||||
接收到审核 | 366(322~1 569) | 1 698 | 214(147~279) | 359* | ||
录入到审核 | 308(249~352) | 385 | 128(90~191) | 241* | ||
8:00—15:00接收 | 866 | 121 | ||||
但未出报告 | ||||||
接收到审核 | 1 661(1 610~1 780) | 3 186 | 1 530(1 404~1 606) | 1 775* | ||
录入到审核 | 350(257~396) | 413 | 163(95~299) | 354* |
[1] | LI M,WANG Z Q,ZHANG L,et al.Burden of cirrhosis and other chronic liver diseases caused by specific etiologies in China,1990-2016:findings from the global burden of disease study 2016[J]. Biomed Environ Sci,2020,33(1):1-10. |
[2] | World Health Organization. Hepatitis B [EB/OL]. (2019-07-08)[2019-08-01]. . |
[3] | CUI Y,JIA J.Update on epidemiology of hepatitis B and C in China[J]. J Gastroenterol Hepatol,2013,28(Suppl 1):7-10. |
[4] | SARIN S K,KUMAR M,ESLAM M,et al.Liver diseases in the Asia-Pacific region:a Lancet Gastroenterology & Hepatology Commission[J]. Lancet Gastroenterol Hepatol,2020,5(2):167-228. |
[5] | 中华人民共和国国家卫生和计划生育委员会. WS/T 420—2013 临床实验室对商品定量试剂盒分析性能的验证[S]. 北京:中华人民共和国国家卫生和计划生育委员会,2013. |
[6] | 中华人民共和国国家卫生和计划生育委员会. WS/T 492—2016 临床检验定量测定项目精密度与正确度性能验证[S]. 北京:中华人民共和国国家卫生和计划生育委员会,2016. |
[7] | 中华人民共和国国家卫生和计划生育委员会. WS/T494—2017 临床定性免疫检验重要常规项目分析质量要求[S]. 北京:中华人民共和国国家卫生和计划生育委员会,2017. |
[8] | 中国合格评定国家认可委员会. CNAS-GL037:2019 临床化学定量检验程序性能验证指南[S]. 北京:中国合格评定国家认可委员会,2019. |
[9] | 中国合格评定国家认可委员会. CNAS-GL038:2019 临床免疫学定性检验程序性能验证指南[S]. 北京:中国合格评定国家认可委员会,2019. |
[10] | MILER M,NIKOLAC GABAJ N,DUKIC L,et al.Key performance indicators to measure improvement after implementation of total laboratory automation Abbott Accelerator a3600[J]. J Med Syst,2018,42(2):28. |
[11] | 林树波,郑泽旋,张锐. 化学发光免疫分析试验在血液筛查中的应用及评价[J]. 中国实验血液学杂志,2019,27(2):569-572. |
[12] | 刘杨,彭道荣,马越云,等. 2种HBsAg定量检测系统对HBV不同感染阶段及不同基因型样本检测的一致性评价[J]. 检验医学,2016,31(4):288-292. |
[1] | TANG Qingqin, QIAO Longwei, YIN Jingping, ZHANG Sheng, FENG Bin, LIANG Yuting. Correlation of peripheral blood monocyte count and serum anti-phospholipase A2 receptor antibody in patients with nephrotic syndrome [J]. Laboratory Medicine, 2023, 38(7): 647-652. |
[2] | WANG Haiping, LI He. BISAP score combined with serum sRAGE for predicting hyperlipidemic acute pancreatitis severity and short-term prognosis [J]. Laboratory Medicine, 2023, 38(7): 653-658. |
[3] | WU Jie, LI Zenghe, CHEN Baorong, KONG Xujing. Establishment of traceable steroid hormone standard curve for dried blood spot samples [J]. Laboratory Medicine, 2023, 38(5): 489-493. |
[4] | . [J]. Laboratory Medicine, 2023, 38(3): 291-293. |
[5] | . [J]. Laboratory Medicine, 2023, 38(1): 100-102. |
[6] | . [J]. Laboratory Medicine, 2022, 37(9): 892-893. |
[7] | SUN Xiaodan, LIU Yiwen, HE Yiqing, DU Yan, ZHANG Guoliang, GAO Feng, YANG Cuixia. Research progress on the role of estrogen receptor in osteosarcoma [J]. Laboratory Medicine, 2022, 37(4): 313-318. |
[8] | SUN Xiaodan, XU Jing, LIU Yiwen, HE Yiqing, DU Yan, ZHANG Guoliang, GAO Feng, YANG Cuixia. Inhibitory effects of antiestrogen on the proliferation and CCL2 expression of osteosarcoma cells [J]. Laboratory Medicine, 2022, 37(4): 319-324. |
[9] | CHEN Si, LIU Hua, LIU Yiwen, HE Yiqing, ZHANG Guoliang, YANG Cuixia, DU Yan, GAO Feng. Clinical significance of combined determination of serum HER-2 and CD44 in colorectal cancer [J]. Laboratory Medicine, 2022, 37(4): 336-341. |
[10] | ZHAO Mingna, ZHANG Chenzi, HONG Qiushuang, LOU Jiatao. Mechanism of IL-8/miR-182 positive feedback regulatory axis in non-small cell lung cancer [J]. Laboratory Medicine, 2022, 37(4): 349-355. |
[11] | ZHANG Zhibin, YANG Wanyong, RUAN Fuwang, WEN Qinghui. Roles of total IgE,sIgE and 25(OH)D in the evaluation of infant atopic dermatitis [J]. Laboratory Medicine, 2022, 37(3): 217-220. |
[12] | . [J]. Laboratory Medicine, 2021, 36(12): 1264-1266. |
[13] | QIU Fang, ZHU Ping, JIANG Peng, WANG Chan. Relation between anti-gp210 antibody,anti-sp100 antibody and ALBI score in patients with primary biliary cholangitis [J]. Laboratory Medicine, 2021, 36(11): 1106-1109. |
[14] | . [J]. Laboratory Medicine, 2021, 36(9): 925-928. |
[15] | LIU Yang, ZHANG Zhiping, PENG Daorong, SONG Liuwei, GE Shengxiang, HAO Xiaoke, LIU Jiayun. Establishment and performance evaluation of chemiluminescent microparticle immunoassay for the determination of high concentration HbsAg [J]. Laboratory Medicine, 2020, 35(10): 1056-1061. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||